Literature DB >> 9737780

Molecular and clinical study of 183 patients with conotruncal anomaly face syndrome.

R Matsuoka1, M Kimura, P J Scambler, B E Morrow, S Imamura, S Minoshima, N Shimizu, H Yamagishi, K Joh-o, S Watanabe, K Oyama, T Saji, M Ando, A Takao, K Momma.   

Abstract

To investigate molecular and clinical aspects of conotruncal anomaly face (CAF), we studied the correlation between deletion size and phenotype and the mode of inheritance in 183 conotruncal anomaly face syndrome (CAFS) patients. Hemizygosity for a region of 22ql1.2 was found in 180 (98%) of the patients with CAFS by fluorescence in situ hybridization (FISH) using the N25(D22S75) DiGeorge critical region (DGCR) probe. No hemizygosity was found in three (2%) of the patients with CAFS by FISH using nine DiGeorge critical region probes and a SD1OP1 probe (DGA II locus). None of these three patients had mental retardation and just one had nasal intonation, which was observed in almost all of the 180 CAFS patients who carried deletions (mental retardation, 92%; nasal voice, 88%). Nineteen of 143 families (13%) had familial CAFS and 16 affected parents (84%) were mothers. Although only two of the affected parents had cardiovascular anomalies, the deletion size in the 16 affected parents and their affected family members, who were studied by FISH analysis, was the same. It indicates that extragenic factors may play a role in the genesis of phenotypic variability, especially in patients with cardiovascular anomalies. No familial cases were found among CAFS patients with absent thymus/DiGeorge anomaly (DGA). Also, in all 18 CAFS patients with completely absent thymus/DGA and all 6 CAFS patients with schizophrenia, it was revealed that the deletion was longer distally. A study of the origin of the deletion using microsatellite analyses in 48 de novo patients showed that in 65% of CAFS patients it was maternal, while in 64% of DGA patients it was paternal. The findings of this study indicated that CAF was almost always associated with the deletion of 22ql1.2. As well as the major features of the syndrome, other notable extracardiac anomalies were found to be susceptibility to infection, schizophrenia, atrophy or dysmorphism of the brain, thrombocytopenia, short stature, facial palsy, anal atresia, and mild limb abnormalities.

Entities:  

Mesh:

Year:  1998        PMID: 9737780     DOI: 10.1007/s004390050786

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  22 in total

1.  Sixteen New Cases Contributing to the Characterization of Patients with Distal 22q11.2 Microduplications.

Authors:  J Wincent; D L Bruno; B W M van Bon; A Bremer; H Stewart; E M H F Bongers; C W Ockeloen; M H Willemsen; D D A Keays; G Baird; D F Newbury; T Kleefstra; C Marcelis; U Kini; Z Stark; R Savarirayan; L J Sheffield; O Zuffardi; H R Slater; B B de Vries; S J L Knight; B-M Anderlid; J Schoumans
Journal:  Mol Syndromol       Date:  2011-05-18

2.  Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome.

Authors:  Rosanna Weksberg; Andrea C Stachon; Jeremy A Squire; Laura Moldovan; Jane Bayani; Stephen Meyn; Eva Chow; Anne S Bassett
Journal:  Hum Genet       Date:  2006-10-07       Impact factor: 4.132

3.  Clinical features of 78 adults with 22q11 Deletion Syndrome.

Authors:  Anne S Bassett; Eva W C Chow; Janice Husted; Rosanna Weksberg; Oana Caluseriu; Gary D Webb; Michael A Gatzoulis
Journal:  Am J Med Genet A       Date:  2005-11-01       Impact factor: 2.802

4.  No evidence for parental imprinting of mouse 22q11 gene orthologs.

Authors:  Thomas M Maynard; Daniel W Meechan; Clifford C Heindel; Amanda Z Peters; Robert M Hamer; Jeffrey A Lieberman; Anthony-Samuel LaMantia
Journal:  Mamm Genome       Date:  2006-08-04       Impact factor: 2.957

Review 5.  Phenotype of adults with the 22q11 deletion syndrome: A review.

Authors:  E Cohen; E W Chow; R Weksberg; A S Bassett
Journal:  Am J Med Genet       Date:  1999-10-08

Review 6.  Congenital heart diseases and cardiovascular abnormalities in 22q11.2 deletion syndrome: From well-established knowledge to new frontiers.

Authors:  Marta Unolt; Paolo Versacci; Silvia Anaclerio; Caterina Lambiase; Giulio Calcagni; Matteo Trezzi; Adriano Carotti; Terrence Blaine Crowley; Elaine H Zackai; Elizabeth Goldmuntz; James William Gaynor; Maria Cristina Digilio; Donna M McDonald-McGinn; Bruno Marino
Journal:  Am J Med Genet A       Date:  2018-04-16       Impact factor: 2.802

7.  22q11.2 deletion syndrome in diverse populations.

Authors:  Paul Kruszka; Yonit A Addissie; Daniel E McGinn; Antonio R Porras; Elijah Biggs; Matthew Share; T Blaine Crowley; Brian H Y Chung; Gary T K Mok; Christopher C Y Mak; Premala Muthukumarasamy; Meow-Keong Thong; Nirmala D Sirisena; Vajira H W Dissanayake; C Sampath Paththinige; L B Lahiru Prabodha; Rupesh Mishra; Vorasuk Shotelersuk; Ekanem Nsikak Ekure; Ogochukwu Jidechukwu Sokunbi; Nnenna Kalu; Carlos R Ferreira; Jordann-Mishael Duncan; Siddaramappa Jagdish Patil; Kelly L Jones; Julie D Kaplan; Omar A Abdul-Rahman; Annette Uwineza; Leon Mutesa; Angélica Moresco; María Gabriela Obregon; Antonio Richieri-Costa; Vera L Gil-da-Silva-Lopes; Adebowale A Adeyemo; Marshall Summar; Elaine H Zackai; Donna M McDonald-McGinn; Marius George Linguraru; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2017-04       Impact factor: 2.802

8.  Hemizygosity for the gene encoding glycoprotein Ibβ is not responsible for macrothrombocytopenia and bleeding in patients with 22q11 deletion syndrome.

Authors:  N M J Zwifelhofer; R S Bercovitz; L A Weik; A Moroi; S LaRose; P J Newman; D K Newman
Journal:  J Thromb Haemost       Date:  2019-01-22       Impact factor: 5.824

9.  Hippocampal malrotation is associated with chromosome 22q11.2 microdeletion.

Authors:  Danielle M Andrade; Timo Krings; Eva W C Chow; Tim-Rasmus Kiehl; Anne S Bassett
Journal:  Can J Neurol Sci       Date:  2013-09       Impact factor: 2.104

10.  Three patients with oculo-auriculo-vertebral spectrum and microdeletion 22q11.2.

Authors:  M Cristina Digilio; Donna M McDonald-McGinn; Carrie Heike; Charles Catania; Bruno Dallapiccola; Bruno Marino; Elaine H Zackai
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.